Page last updated: 2024-12-08

cryptoporic acid e

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cryptoporic acid E: from fungus Cryptoporus volvatus; inhibitor of superoxide anion radical release; inhibits tumor promotion of okadaic acid; RN given from Chem Abstr Index Guide 1991; RN given refers to (1S-(1alpha(1S*,2R*),4alpha, beta,5beta(2R*,3S*(1R*,4aS*,5S*,8aR))8aalpha))-isomer; RN for cpd without isomeric designation not avail 7/91 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID147476
CHEMBL ID4868875
SCHEMBL ID20576741
MeSH IDM0188947

Synonyms (9)

Synonym
cryptoporic acid e
(3s,4r)-4-[[(1s,4ar,5r,8as)-5-[[(2s,3r)-3-[[(1s,4ar,5r,8as)-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1h-naphthalen-1-yl]methoxy]-2-(carboxymethyl)-4-methoxy-4-oxobutanoyl]oxymethyl]-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexa
120001-10-7
1,2,3-propanetricarboxylic acid, 1-((5-((2-(carboxymethyl)-3-((decahydro-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl)methoxy)-4-methoxy-1,4-dioxobutoxy)methyl)decahydro-5,8a-dimethyl-2-methylene-1-naphthalenyl)methoxy)-, 1,2-dimethyl ester,
ccris 6990
4r12b7j65a ,
unii-4r12b7j65a
SCHEMBL20576741
CHEMBL4868875

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Treatment with cryptoporic acid E using two different doses per application, 1 (1.2 mumol) and 5 mg (5.9 mumol), reduced the percentage of tumor-bearing mice from 73.3 to 53.3% and 20.0%, and the average number of tumors per mouse from 4.2 to 2.3 and 0.5 respectively in week 20 of tumor promotion."( Differential effects of cryptoporic acids D and E, inhibitors of superoxide anion radical release, on tumor promotion of okadaic acid in mouse skin.
Asakawa, Y; Fujiki, H; Furuya-Suguri, H; Hashimoto, T; Matsunaga, S; Nishiwaki, S; Suganuma, M; Yoshizawa, S, 1991
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1753117Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay2021Journal of natural products, 02-26, Volume: 84, Issue:2
Species Prioritization Based on Spectral Dissimilarity: A Case Study of Polyporoid Fungal Species.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (60.00)18.2507
2000's0 (0.00)29.6817
2010's1 (20.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.87 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]